Get the Stockscreener App
13.36
1.44%
0.19
After Hours:
13.45
0.09
+0.67%
Myriad Genetics Inc stock is traded at $13.36, with a volume of 3.29M.
It is up +1.44% in the last 24 hours and down -12.68% over the past month.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
See More
Previous Close:
$13.17
Open:
$13.04
24h Volume:
3.29M
Relative Volume:
3.74
Market Cap:
$1.22B
Revenue:
$802.20M
Net Income/Loss:
$-155.20M
P/E Ratio:
-3.9762
EPS:
-3.36
Net Cash Flow:
$-141.30M
1W Performance:
-7.42%
1M Performance:
-12.68%
6M Performance:
-43.87%
1Y Performance:
-34.25%
1-Day Range:
$13.04
$13.56
1-Week Range:
$12.87
$14.54
52-Week Range:
$12.87
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
13.36 | 1.22B | 802.20M | -155.20M | -141.30M | -1.81 |
|
TMO
Thermo Fisher Scientific Inc
|
524.05 | 200.45B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
228.55 | 165.08B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
134.51 | 38.36B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.27 | 35.80B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
412.26 | 33.76B | 3.84B | 866.24M | 792.60M | 10.37 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Barclays PLC Raises Stake in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
MYGN Stock Might Gain From the New Recognition of RiskScore Study - Yahoo Finance
PARP Inhibitor Biomarkers Market Investment Outlook: Industry - openPR
Pancreatic Cancer Market Analysis 2024: Trends, Growth, and Key - openPR
Myriad Genetics’ RiskScore Study Named One of the Top 10 - GlobeNewswire
Myriad Genetics' Breakthrough Cancer Test Named Top 10 Genomic Advance by Leading Journal - StockTitan
Hereditary Cancer Testing Market: Pioneering Early Detection and Prevention Strategies - openPR
Myriad Genetics (NASDAQ:MYGN) Sets New 1-Year LowTime to Sell? - MarketBeat
Myriad Genetics stock hits 52-week low at $13.86 amid challenges - Investing.com Canada
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now? - Yahoo Finance
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
Myriad Genetics stock hits 52-week low at $13.86 amid challenges By Investing.com - Investing.com South Africa
Clinical Oncology Next Generation Sequencing Market Top - openPR
How To Trade (MYGN) - Stock Traders Daily
State Street Corp Buys 359,685 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Price Target Lowered to $13.00 at Bank of America - MarketBeat
Why Myriad Genetics, Inc. Shares Soared - AOL
Analysts Offer Predictions for Myriad Genetics Q1 Earnings - MarketBeat
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing - The Manila Times
Myriad Genetics Provides Update on Discussions with - GlobeNewswire
Myriad Genetics Fights to Preserve GeneSight Coverage as UnitedHealthcare Plans 2025 Restrictions - StockTitan
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member - The Manila Times
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock To Gain? - Barchart
Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines - The Manila Times
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines - GlobeNewswire
Myriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by Leerink Partnrs - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Coverage Initiated by Analysts at UBS Group - MarketBeat
Disciplined Growth Investors Inc. MN Purchases 440,107 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain? - Yahoo Finance
Cancer Biopsy Market Trends, Key Drivers, and Regional Outlook - openPR
PARP Inhibitor Biomarkers Market Key Players AnalysisMyriad - openPR
Pharmacogenomics Global Market Report: Key Insights and Market - openPR
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium - The Manila Times
Myriad Genetics Unveils Breakthrough Breast Cancer Detection Tools at SABCS 2024 - StockTitan
Myriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by Leerink Partners - MarketBeat
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment - The Manila Times
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad - GlobeNewswire
Myriad Genetics' Prolaris Test Retains Elite NCCN Status for 10th Year in Prostate Cancer Diagnosis - StockTitan
Wellington Management Group LLP Sells 1,545,842 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month LowWhat's Next? - MarketBeat
Shareholders in Myriad Genetics (NASDAQ:MYGN) have lost 41%, as stock drops 7.0% this past week - Simply Wall St
Myriad Genetics stock hits 52-week low at $14.54 amid market shifts - Investing.com Canada
RSI Alert: Myriad Genetics (MYGN) Now Oversold - Nasdaq
Myriad Genetics stock hits 52-week low at $14.54 amid market shifts By Investing.com - Investing.com South Africa
Point72 Asset Management L.P. Grows Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Verition Fund Management LLC Has $2.44 Million Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Charles Schwab Investment Management Inc. Acquires 41,374 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
How to Take Advantage of moves in (MYGN) - Stock Traders Daily
Edgestream Partners L.P. Makes New Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View - MSN
Fisher Asset Management LLC Boosts Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):